Physician profile
Alexander Escobar
NPI 1790049229
$638,046.63
in general payments reported to CMS, 2019-2025
36 companies · $148K in 2025
The $148K reported for 2025 was more than what 99% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $61K · 2021: $45K · 2022: $102K · 2023: $77K · 2024: $114K · 2025: $148K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $149K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $54K · Travel and Lodging: $47K · Food and Beverage: $12K · Education: $9,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $148,550.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,905.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $53,930.00 |
| Travel and Lodging | $47,060.90 |
| Food and Beverage | $12,049.49 |
| Education | $9,957.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $244,737.02 | 2019-2024 | Senza, Vyrsa V1, Omnia |
| Vertos Medical, INC. | $97,833.11 | 2019-2024 | Mild Device Kit |
| Globus Medical, INC. | $90,866.05 | 2025 | Senza, Vyrsa V1, Corridor |
| Stryker Corporation | $57,540.98 | 2019-2025 | Mild Device Kit, Spinejack, Optablate |
| Abbott Laboratories | $56,157.32 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Medtronic, INC. | $27,559.59 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $21,696.30 | 2019-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, Na |
| Painteq LLC | $20,605.26 | 2021-2024 | Painteq |
| Vertiflex, INC. | $18,580.93 | 2019 | |
| Medtronic USA, INC. | $441.64 | 2019-2020 | |
| Nalu Medical, INC. | $263.30 | 2021-2024 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $251.06 | 2022-2024 | Sprint Pns System |
| Spinal Simplicity, LLC | $240.10 | 2020-2025 | Ha Minuteman G3-R |
| Pfizer INC. | $186.48 | 2019-2021 | |
| Stratus Medical, LLC | $179.86 | 2024 | Nimbus |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $129.25 | 2021-2022 | |
| Allergan, INC. | $104.22 | 2019-2022 | |
| Axonics, INC. | $76.46 | 2021 | |
| Biotronik Nro, INC. | $65.40 | 2025 | Prospera |
| Relievant Medsystems, INC. | $54.25 | 2021 | |
| Tersera Therapeutics LLC | $53.38 | 2024-2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $53.26 | 2024-2025 | |
| Averitas Pharma INC. | $45.28 | 2023-2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $44.91 | 2019-2020 | |
| Si-Bone, INC. | $39.07 | 2020-2025 | |
| Grt US Holding, INC. | $35.49 | 2022 | |
| Almatica Pharma LLC | $34.11 | 2021 | |
| Amgen INC. | $26.00 | 2019 | |
| Foundation Fusion Solutions, LLC | $23.77 | 2025 | |
| Mml US, INC. | $23.44 | 2025 | Reactiv8 |
| Scilex Pharmaceuticals INC. | $18.99 | 2019 | |
| Radius Health, INC. | $17.77 | 2021 | |
| Ethicon US, LLC | $17.34 | 2024 | Stratafix, Ethicon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.73 | 2019 | |
| Ibsa Pharma INC. | $15.91 | 2021 | |
| Biodelivery Sciences International, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.